Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor – Case Report and Review of the Literature

Ludmila Tankova¹, Vanya Gerova¹, Plamen Getsov², Radislav Nakov^1, , Stanislav Churchev¹, Ivan Terziev³, Irena Kostadinova⁴, Miroslava Vitkova¹, Ventsislav Nakov¹, Damyan Damyanov¹ and Nina Topuzanska¹

¹Clinical Center of Gastroenterology, University Hospital, “Queen Joanna”, Sofia, Bulgaria

²Department of Radiology, University Hospital, “Queen Joanna”, Sofia, Bulgaria

³Department of Pathology, University Hospital, “Queen Joanna”, Sofia, Bulgaria

⁴Medical University, Central Laboratory of Nuclear Medicine, Sofia, Bulgaria

Cite this paper:
Ludmila Tankova, Vanya Gerova, Plamen Getsov, Radislav Nakov, Stanislav Churchev, Ivan Terziev, Irena Kostadinova, Miroslava Vitkova, Ventsislav Nakov, Damyan Damyanov and Nina Topuzanska. Metastatic Nonfunctional Pancreatic Neuroendocrine Tumor – Case Report and Review of the Literature. American Journal of Medical Case Reports. 2015; 3(7):205-208. doi: 10.12691/ajmcr-3-7-6

Abstract

We present a 56-year-old patient with liver metastases from nonfunctional pancreatic neuroendocrine tumor. The disease is found incidentally in a patient with nonspecific symptoms. Conventional abdominal ultrasound establishes several liver lesions mimicking hemangiomas. On contrast enhancement ultrasonography hypervascularized secondary liver lesions are detected. Subsequent imaging methods and biochemical tests diagnose a pancreatic neuroendocrine metastatic tumor. Left-sided pancreatectomy with splenectomy is carried out. The patient is in good general condition six months after initiation of combination therapy with everolimus and sandostatin LAR depot. Tc-99m-tektrotyd single photon emission computed tomography-CT hybrid imaging shows reduced accumulation of the radiopharmaceutical in the liver parenchyma without data of pancreatic tumor.

Keywords:
neuroendocrine tumor pancreas liver metastases imaging methods

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Panzuto, F., Nasoni, S., Falconi, M., et al., “Prognostic factors and survival in endocrine tumor patients: Comparison between gastrointestinal and pancreatic localization,” Endocr Relat Cancer, 12, 1083-1092, 2005.
[2]	Eriksson, B. and Oberg, K, “Neuroendocrine tumours of the pancreas,” Br J Surg, 87 (2), 129-131, Feb 2000.
[3]	Davies, K. and Conlon, K.C., “Neuroendocrine tumors of the pancreas,” Current Gastroenterology Reports, 11 (2), 119-127, Apr 2009.
[4]	Halfdanarson, T.R., Rabe, K.G., Rubin, J. and Petersen, G.M., “Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival,” Annals of Oncology, 19 (10), 1727-33, Oct 2008.
[5]	Modlin, I.M., Lye, K.D. and Kidd, M, “А 5-decade analysis of 13,715 carcinoid tumors,” Cancer, 97 (4), 934-959, Feb 2003.
[6]	Kaltsas, G.A., Besser, G.M. and Grossman, A.B., “The diagnosis and medical management of advanced neuroendocrine tumors,” Endocr Rev, 25 (3), 458-511, Jun 2004.
[7]	Dixon, E. and Pasieka, J.L., “Functioning and nonfunctioning neuroendocrine tumors of the pancreas,” Curr Opin Oncol, 19 (1), 30-5, Jan 2007.
[8]	Rindi, G., Arnold, R., Bosman, F.T., et al., Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, et al. eds. WHO classification of tumors of the digestive system. Lyon: International Agency for Research on Cancer (IRAC), 2010, 13-145.
[9]	Klimstra, D.S., Beltran, H., Lilenbaum, R. and Bergsland, E., “The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap,” Am Soc Clin Oncol Educ Book, 35, 92-103, 2015.
[10]	Pavel, M., Baudin, E., Couvelard, A., et al., “ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary,” Neuroendocrinology, 95, 157-76, 2012.
[11]	van Essen, M., Sundin, A., Krenning, E.P. and Kwekkeboom, D.J., “Neuroendocrine tumours: the role of imaging for diagnosis and therapy,” Nat Rev Endocrinol, 10 (2), 102-114, Feb 2014.
[12]	Kartalis, N., Mucelli, R.M.P. and Sundin, A., “Recent developments in imaging of pancreatic neuroendocrine tumors,” Ann Gastroenterol, 28 (2), 193-202, Apr-Jun 2015.
[13]	John, B.J. and Davidson, B.R., “Treatment options for unresectable neuroendocrine liver metastases,” Expert Rev Gastroenterol Hepatol, 6 (3), 357-69, Jun 2012.
[14]	Hori, T., Takaori, K. and Uemoto, S. “Pancreatic neuroendocrine tumor accompanied with multiple liver metastases,” World J Hepatol, 6 (8), 596-600, Aug 2014.
[15]	Kimura, W., Tezuka, K. and Hirai, I., “Surgical management of pancreatic neuroendocrine tumors,” Surg Today, 41 (10), 1332-1343, Oct 2011.
[16]	Bettini, R., Mantovani, W., Boninsegna, L., Crippa, S., Capelli, P., Bassi, C., Scarpa, A., Pederzoli, P. and Falconi, M., “Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas,” Dig Liver Dis 2009; 41: 49-55.
[17]	Yao, JC., Shah, MH.., Ito, Y., Bohas, CL., Wolin, EM., Cutsem, EV., Hobday, T.J. et al., Okusaka, T., Capdevila, J., de Vries, E, Tomassetti, P., Pavel, ME., Hoosen, S. et al, “Everolimus for Advanced Pancreatic Neuroendocrine Tumors,” N Engl J Med, 364 (1), 514-523, Jan 2011.
[18]	Yao, J.C., Phan, A.T., Jehl, V., Shah, G. and Meric-Bernstam, F., “Everolimus in advanced pancreatic neuroendocrine tumors: the clinical experience,” Cancer Res, 73 (5), 1449-1453, Mar 2013.
[19]	Panzuto, F., Rinzivillo, M., Fazio, N., de Braud, F., Luppi, G., Zatelli, M.C. and Lugli, F. “Real-world study of everolimus in advanced progressive neuroendocrine tumors,” Oncologist, 19 (9), 966-74, Sep 2014.